Rebel investors trying to hijack SkyePharma, chairman claims
The embattled drug developer has set a date of 9 March for the extraordinary meeting requested by the dissidents after delaying the shareholder circular for two days to give them time to back down.
The board is urging investors to vote against the appointment of Bob Thian, the chairman of the filtration-paper company Whatman, as a director. The rebels plan to install him as an executive chairman.
The dissidents ousted the founder and previous chairman of SkyePharma, Ian Gowrie-Smith. But the company then snubbed them by appointing Mr Karabelas, who has sat on the board for five years as non-executive chairman.
Mr Karabelas said yesterday: "I don't know how an executive chairman who has made a deal with the minority shareholders is going to work in the interest of all shareholders. It's an attempt to hijack the company under the guise of, 'We are the owners of the company'. He added: "These are attempts to take over the company without a premium."
The dissident group comprises North Atlantic Value (NAV), part of JO Hambro, Morley and Insight, and represents 14.2 per cent of SkyePharma shares. NAV was behind Mr Thian's appointment to Whatman. He is credited with making big improvements there, although a recent profits warning cast doubt on his achievements and Whatman has had three chief executives in two years.
Mr Karabelas claimed Mr Thian was the rebel group's second-choice candidate, saying: "Here's a chairman who has difficulty keeping CEOs. In baseball it's three strikes and you're out."
NAV stressed the credentials of Mr Thian and argued: "Many of the executive management team associated with SkyePharma's dismal track record continue to be members of the board.... It is imperative that a totally independent chairman is appointed immediately to give shareholders confidence that these serious issues will be addressed as soon as possible."
SkyePharma's future hinges on HBM Bioventures, the Swiss venture-capital group headed by the former Roche finance director Henri Meier. It is the single largest shareholder in SkyePharma, with a 9.3 per cent stake. Mr Karabelas flew to Switzerland last Friday accompanied by his new chief executive, Frank Condella. Mr Karabelas was quietly confident HBM would back the board, saying: "It was a very successful meeting." NAV has also been to Switzerland to try to win HBM's support.
Mr Karabelas admitted: "Clearly there is disappointment about what's happened to the share price. That's something I'm very sympathetic to."
In pictures: Saturn images from Cassini probe as it prepares to turn lens towards Earth
Serena Williams apologises after comment that rape victim 'shouldn't have put herself in that position'
New banker bonus boom: Payouts leapt 64% to new record when Chancellor George Osborne cut top-rate tax to 45p in April
'Theres something quite unpleasant going on': Nigel Farage confronted for second time on visit to Scotland
World news in pictures
- 1 Breaking the Silence: In the reality of occupation, there are no Palestinian civilians – only potential terrorists
- 2 Mike Ashley wants blood after last season's trauma at Newcastle - and it won't stop with Derek Llambias
- 3 Richard Nieuwenhuizen death: Six teenagers and 50-year-old father convicted of manslaughter in shocking case of referee killed over a game of football
- 4 Exclusive: Newcastle's star talent-spotter on brink as Joe Kinnear sparks walkout
- 5 Vast methane 'plumes' seen in Arctic ocean as sea ice retreats
iJobs Money & Business
£500 - £600 per day: Orgtel: FX Options Front Office Java / C# Developer - Ba...
£600 - £700 per day: Orgtel: Project Manager - Front Office - Regulatory IT C...
£600 - £750 per day: Orgtel: FATCA Project Manager - Banking - London - £600-...
£550 - £600 per day: Orgtel: Fidessa Analyst / PM - Banking - London - Up to £...